RECRUITING Not applicable ClinicalTrials.gov

EFFECT OF ESWT ON BREAST-CANCER RELATED LYMPHEDEMA

Sponsor: Ankara City Hospital Bilkent • ClinicalTrials.gov ID: NCT07854262

Registry updated: 2026-10-02

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

The aim of this study is to evaluate the effectiveness of extracorporeal shock wave therapy (ESWT) combined with complete decongestive therapy (CDT) compared with CDT alone in patients with breast cancer-related lymphedema. Female patients with unilateral Stage II upper-extremity lymphedema related to breast cancer will be included. Participants will receive either complete decongestive therapy alone or complete decongestive therapy combined with extracorporeal shock wave therapy. Clinical outcomes will be evaluated before treatment, immediately after treatment, and at 1 and 3 months after treatment. Primary outcomes will include limb circumference difference, volumetric measurements, and ultrasonographic assessment of skin and subcutaneous tissue thickness. Secondary outcomes will include upper-extremity function, quality of life, and pain.

Interventions

Complete Decongestive Therapy (Other)
Complete decongestive therapy will consist of manual lymphatic drainage performed by an experienced physiotherapist according to the Vodder technique for 45-60 minutes, followed by multilayer short-stretch bandaging and lymphedema exercises performed under the supervision of the physiotherapist. Treatment will be administered five sessions per week for a total of 15 sessions. Arm Cross-Reference: Complete Decongestive Therapy Complete Decongestive Therapy Plus Extracorporeal Shock Wave Therapy
Extracorporeal Shock Wave Therapy (Device)
Radial extracorporeal shock wave therapy will be administered using a pressure of 2 bar, a frequency of 4 Hz, and a total of 2,500 shocks per session. The shocks will be distributed as follows: Axillary region: 750 shocks Upper arm: 500 shocks Cubital region: 250 shocks Forearm: 500 shocks Dorsum of the hand: 500 shocks ESWT will be administered three sessions per week for three weeks. Arm Cross-Reference: Complete Decongestive Therapy Plus Extracorporeal Shock Wave Therapy

Eligibility criteria

Inclusion Criteria:Female patients with unilateral upper-extremity lymphedema related to breast cancer. At least 2 years have elapsed since the diagnosis of breast cancer, cancer treatment has been completed, and cure has been documented during oncology follow-up. Stage II lymphedema according to the International Society of Lymphology classification. Duration of lymphedema of less than 4 years. Voluntary participation in the study. - Exclusion Criteria: Poor general health status. Open wounds, sensory deficits, or other conditions in the treatment area that may constitute a contraindication to treatment. Active infection. Presence of metastasis. Bilateral breast cancer. Bilateral lymphedema. Use of anticoagulant therapy or presence of a coagulation disorder. Cognitive impairment that may prevent completion of study assessment procedures. Physical therapy, including electrotherapy or exercise therapy, ESWT, or regular use of nonsteroidal anti-inflammatory drugs within the previous 6 months. Systemic inflammatory or autoimmune disorders such as rheumatoid arthritis or systemic lupus erythematosus. \-

Conditions

Breast Cancer Related Lymphedema

Locations

Ankara Bilkent City Hospital, Physical Medicine and Rehabilitation Hospital — Ankara, Turkey (Türkiye)

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment